Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19769054 | 0.81 | ADRA2A (0.35) | RET | |
| SCHEMBL19769066 | 0.81 | ADRA2A (0.35) | RET | |
| SCHEMBL19880469 | 0.77 | ALDH1A1 (0.49) | ALDH1A1FGF23L3MBTL1HPGDTSHR | |
| SCHEMBL19769027 | 0.77 | ALDH1A1 (0.49) | ALDH1A1FGF23L3MBTL1HPGDTSHR | |
| SCHEMBL24833024 | 0.77 | CCR1 (0.41) | ALDH1A1 | |
| SCHEMBL20621313 | 0.77 | NOS3 (0.31) | — | |
| SCHEMBL19779245 | 0.77 | NOS3 (0.31) | — | |
| SCHEMBL23693838 | 0.76 | HRH4 (0.36) | — | |
| SCHEMBL21709897 | 0.73 | SMN1; SMN2 (0.39) | ALDH1A1FGF23KDM4EALOX15L3MBTL1 | |
| SCHEMBL31043414 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-10464918-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464918-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | ALDH1A1 4601/4885FGF23 494/4885RET 996/4885 |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | ALDH1A1 4601/4885FGF23 494/4885RET 996/4885 |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | ALDH1A1 4601/4885FGF23 494/4885RET 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.